Key Points
- Use the highest‑yield diagnostic test early; do not let testing delay time‑critical therapy.
- Set objective targets and reassess frequently.
- Plan definitive source control or disease‑specific therapy when indicated; document follow‑up and patient education.
Algorithm
- Suspect dissection → control HR then BP; obtain emergent imaging.
- Type A → emergent surgery; Type B → medical therapy unless rupture, malperfusion, refractory pain/HTN → consider TEVAR.
- ICU monitoring and genetic evaluation for aortopathy as indicated.
Clinical Synopsis & Reasoning
Tearing chest/back pain with pulse deficits or mediastinal widening suggests dissection. Rapidly control HR (<60) and SBP (100–120) with beta-blockade and vasodilators; obtain CTA chest/abdomen/pelvis. Type A requires emergent surgery; Type B usually medical unless complications warrant TEVAR.
Treatment Strategy & Disposition
Stabilize ABCs. Initiate guideline‑concordant first‑line therapy with precise dosing and continuous monitoring. Escalate to advanced/procedural interventions based on explicit failure criteria. Define ICU, step‑down, and ward disposition triggers; involve specialty teams early.
Epidemiology / Risk Factors
- Risk varies by comorbidity and precipitants; see citations for condition‑specific data.
Investigations
| Test | Role / Rationale | Typical Findings | Notes |
|---|
| CTA chest/abdomen/pelvis (or TEE/MRA if unstable/contraindications) | Diagnosis | Intimal flap, true/false lumen | Extent and branch involvement |
| ECG, troponin, bedside US | Differential | Rule out ACS/tamponade | Guide therapy |
| Labs including type & cross | Preparation | Potential OR need | — |
High-Risk & Disposition Triggers
| Trigger | Why it matters | Action |
|---|
| Type A dissection or malperfusion | Immediate mortality | CT surgery emergently; ICU |
| Refractory pain or hypertension | Propagation risk | Tight HR/BP control; reassess imaging |
| Neurologic deficit, mesenteric/renal ischemia | Organ threat | Urgent endovascular/surgical plan |
| Pregnancy or genetic aortopathy | High complexity | Multidisciplinary care |
| Suspected rupture/tamponade | Imminent death | Pericardiocentesis generally avoided; OR now |
Pharmacology
| Medication/Intervention | Mechanism | Onset | Role in Therapy | Limitations |
|---|
| Esmolol or Labetalol IV to HR <60 | Rate/impulse control | Minutes | Reduce shear stress first | Add vasodilator after β-blocker |
| Nicardipine/Clevidipine IV for SBP 100–120 | Vasodilation | Minutes | BP target after β-blockade | Avoid reflex tachycardia |
| Pain control (IV opioids) | Analgesia | Minutes | Decrease sympathetic drive | — |
Prognosis / Complications
- Outcome depends on timeliness of diagnosis and definitive therapy; monitor for complications.
Patient Education / Counseling
- Provide red‑flag education, adherence guidance, and explicit return precautions; arrange timely specialty follow‑up.
References
- AHA/ACC aortic disease guideline — Link